NLS Pharmaceutics Announces Publication Of New Patent Application For Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists With The World Intellectual Property Organization
NLS Pharmaceutics Announces Publication Of New Patent Application For Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists With The World Intellectual Property Organization
NLS藥品宣佈與世界知識產權組織共同發表了一份新的專利申請，申請了下一代雙非磺酰胺覺醒素受體激動劑。
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO). The patent will be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs.
瑞士臨床生物製藥公司NLS Pharmaceutics Ltd.（納斯達克：NLSP）（NLSPW），致力於爲罕見和複雜的中樞神經系統疾病開拓療法，今天宣佈，根據其現有和先前宣佈的與Aexon Labs的許可協議，公司將使用由Aexon Labs向世界知識產權組織（WIPO）提交的最新專利申請（PCT/WO2024115797）的專利。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。